Obesity is an epidemic to some and an opportunity to others. More than two-thirds of Americans are overweight. A huge profit might be made from finding a way to fight fat. On February 22nd, one pharmaceutical firm, Vivus, took a small step towards this goal. A committee advising America’s Food and Drug Administration (FDA) recommended that it approve Vivus’s diet drug, Qnexa. However, the pill’s long-awaited final approval may not come until April, if at all. The announcement mostly served as a reminder of what a struggle it is to turn fat into gold.
TOEIC® is a registered trademark of Educational Testing Service(ETS). "TOEIC for Basics" is not endorsed or approved by ETS or The Chauncey Group International Ltd. The TOEIC Program is administered by The Chauncey Group International Ltd.,a subsidiary of Educational Testing Service.